• A Robust Pipeline
 Powered by Brave Science

    Areas of investigation include potential new treatments in neurology, neuroendocrinology, and neuropsychiatry. Our pipeline exemplifies scientific excellence that addresses unmet clinical needs.

    Filter By

    • Phase 1
    • Phase 2
    • Phase 3
    • Neurology
    • Neuropsychiatry
    • Adjunctive Treatment
of Schizophrenia
    • CNS Indications
    • Dyskinetic Cerebral Palsy
    • Epilepsy
    • Inadequate Response to Treatment in Major Depressive Disorder
    • Major Depressive Disorder
    • Movement Disorders
    • Schizophrenia
    |

    • PROGRAM (TARGET)

      valbenazine*
      (VMAT2 Inhibitor)

      THERAPEUTIC AREA

      Neuropsychiatry

      INDICATION

      Adjunctive Treatment
of Schizophrenia
      Phase 1
      Phase 2
      Phase 3
      phase3

    • PROGRAM (TARGET)

      valbenazine*
      (VMAT2 Inhibitor)

      THERAPEUTIC AREA

      Neurology

      INDICATION

      Dyskinetic Cerebral Palsy
      Phase 1
      Phase 2
      Phase 3
      phase3

    • PROGRAM (TARGET)

      osavampator/NBI-'845±
      (AMPA)

      THERAPEUTIC AREA

      Neuropsychiatry

      INDICATION

      Inadequate Response to Treatment in Major
Depressive Disorder
      Phase 1
      Phase 2
      Phase 3
      phase3

    • PROGRAM (TARGET)

      NBI-'568‖
      (M4 Agonist)

      THERAPEUTIC AREA

      Neuropsychiatry

      INDICATION

      Schizophrenia
      Phase 1
      Phase 2
      Phase 3
      phase3

      PROGRAM (TARGET)

      NBI-'570‖
      (M1/M4 Agonist)

      THERAPEUTIC AREA

      Neuropsychiatry

      INDICATION

      Schizophrenia
      – CNS Conditions
      Phase 1
      Phase 2
      Phase 3
      phase1

    • PROGRAM (TARGET)

      NBI-'770§
      (NMDA NR2B NAM)

      THERAPEUTIC AREA

      Neuropsychiatry

      INDICATION

      Major Depressive Disorder
      Phase 1
      Phase 2
      Phase 3
      phase2

    • PROGRAM (TARGET)

      NBI-'567‖,¶
       (M1 Agonist)

      THERAPEUTIC AREA

      Neuropsychiatry

      INDICATION

      CNS Indications
      Phase 1
      Phase 2
      Phase 3
      phase1

      PROGRAM (TARGET)

      NBI-'569‖
      (M4 Agonist)

      THERAPEUTIC AREA

      Neuropsychiatry

      INDICATION

      CNS Indications
      Phase 1
      Phase 2
      Phase 3
      phase1

      PROGRAM (TARGET)

      NBI-'890
      (VMAT2 inhibitor)

      THERAPEUTIC AREA

      Neuropsychiatry

      INDICATION

      CNS Indications
      Phase 1
      Phase 2
      Phase 3
      phase1

      PROGRAM (TARGET)

      NBI-'675
      (VMAT2 Inhibitor)

      THERAPEUTIC AREA

      Neuropsychiatry

      INDICATION

      CNS Indications
      Phase 1
      Phase 2
      Phase 3
      phase1

    • PROGRAM (TARGET)

      NBI-'986
      (M4 Antagonist)

      THERAPEUTIC AREA

      Neurology

      INDICATION

      Movement Disorders
      Phase 1
      Phase 2
      Phase 3
      phase1

    • PROGRAM (TARGET)

      NBI-'355
      (Nav1.2/1.6)

      THERAPEUTIC AREA

      Neurology

      INDICATION

      Epilepsy
      Phase 1
      Phase 2
      Phase 3
      phase1

    Neurocrine Biosciences has global rights unless otherwise noted.

    *Mitsubishi Tanabe Pharma Corporation has commercialization rights in Japan and other select Asian markets.

    ±Takeda Pharmaceutical Company Limited has retained rights in Japan.

    §Licensed from Takeda Pharmaceutical Company Limited.

    ‖Licensed from Nxera Pharma (formerly Sosei Heptares).

    Nxera Pharma (formerly Sosei Heptares) has retained rights in Japan; Neurocrine Biosciences may opt-in to a 50:50 cost and revenue share upon certain development events.

    Download Pipeline Chart

    Investor Relations

    Learn More

    Clinical Studies

    Check Out What We’re Studying

    Career Opportunities

    Work With Us

    You are leaving
    Neurocrine.com

    Exit Site